Cargando…

Association of Fatty Liver Index with Incident Diabetes Risk in Patients Initiating Statin–Therapy: A 6-Year Retrospective Study

Background: Statins are associated with new-onset type 2 diabetes (T2D), mainly in patients with metabolic syndrome (MetS). The fatty liver index (FLI) is used as a prognostic score for the diagnosis of non-alcoholic fatty liver disease (NAFLD), which is common in patients with MetS. We aimed to inv...

Descripción completa

Detalles Bibliográficos
Autores principales: Anastasiou, Georgia, Liberopoulos, Evangelos, Petkou, Ermioni, Koutsogianni, Amalia Despoina, Adamidis, Petros Spyridwnas, Liamis, George, Ntzani, Evangelia, Barkas, Fotios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913972/
https://www.ncbi.nlm.nih.gov/pubmed/36766607
http://dx.doi.org/10.3390/diagnostics13030503
_version_ 1784885554945458176
author Anastasiou, Georgia
Liberopoulos, Evangelos
Petkou, Ermioni
Koutsogianni, Amalia Despoina
Adamidis, Petros Spyridwnas
Liamis, George
Ntzani, Evangelia
Barkas, Fotios
author_facet Anastasiou, Georgia
Liberopoulos, Evangelos
Petkou, Ermioni
Koutsogianni, Amalia Despoina
Adamidis, Petros Spyridwnas
Liamis, George
Ntzani, Evangelia
Barkas, Fotios
author_sort Anastasiou, Georgia
collection PubMed
description Background: Statins are associated with new-onset type 2 diabetes (T2D), mainly in patients with metabolic syndrome (MetS). The fatty liver index (FLI) is used as a prognostic score for the diagnosis of non-alcoholic fatty liver disease (NAFLD), which is common in patients with MetS. We aimed to investigate the association of FLI with new-onset T2D in patients initiating statin therapy. Methods: A retrospective observational study including 1241 individuals with dyslipidemia and followed up for ≥3 years. Patients with T2D and those receiving lipid-lowering treatment at the baseline visit were excluded. Models with clinical and laboratory parameters were used to assess the association of FLI with incident T2D. Results: Among the 882 eligible subjects, 11% developed T2D during the follow-up (6 years; IQR: 4–10 years). After adjusting for sex, age and MetS parameters, a multivariate analysis revealed that age (HR:1.05; 95%CI: 1.01–1.09, p < 0.05), fasting plasma glucose (HR: 1.09; 95%CI: 1.06–1.13, p < 0.001) and FLI (HR: 1.02; 95%CI: 1.01–1.04, p < 0.01) were independently associated with T2D risk. The subjects with probable NAFLD (FLI ≥ 60) had a three-fold increased T2D risk compared with the subjects with FLI < 60 (HR: 3.14; 95%CI: 1.50–6.59, p = 0.001). A ROC curve analysis showed that FLI had a significant, although poor, predictive value for assessing T2D risk (C-Statistic: 0.67; 95%CI: 0.58–0.77, p = 0.001). Higher FLI values were associated with reduced T2D-free survival (log-rank = 15.46, p < 0.001). Conclusions: FLI is significantly and independently associated with new-onset T2D risk in patients initiating statin therapy.
format Online
Article
Text
id pubmed-9913972
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99139722023-02-11 Association of Fatty Liver Index with Incident Diabetes Risk in Patients Initiating Statin–Therapy: A 6-Year Retrospective Study Anastasiou, Georgia Liberopoulos, Evangelos Petkou, Ermioni Koutsogianni, Amalia Despoina Adamidis, Petros Spyridwnas Liamis, George Ntzani, Evangelia Barkas, Fotios Diagnostics (Basel) Article Background: Statins are associated with new-onset type 2 diabetes (T2D), mainly in patients with metabolic syndrome (MetS). The fatty liver index (FLI) is used as a prognostic score for the diagnosis of non-alcoholic fatty liver disease (NAFLD), which is common in patients with MetS. We aimed to investigate the association of FLI with new-onset T2D in patients initiating statin therapy. Methods: A retrospective observational study including 1241 individuals with dyslipidemia and followed up for ≥3 years. Patients with T2D and those receiving lipid-lowering treatment at the baseline visit were excluded. Models with clinical and laboratory parameters were used to assess the association of FLI with incident T2D. Results: Among the 882 eligible subjects, 11% developed T2D during the follow-up (6 years; IQR: 4–10 years). After adjusting for sex, age and MetS parameters, a multivariate analysis revealed that age (HR:1.05; 95%CI: 1.01–1.09, p < 0.05), fasting plasma glucose (HR: 1.09; 95%CI: 1.06–1.13, p < 0.001) and FLI (HR: 1.02; 95%CI: 1.01–1.04, p < 0.01) were independently associated with T2D risk. The subjects with probable NAFLD (FLI ≥ 60) had a three-fold increased T2D risk compared with the subjects with FLI < 60 (HR: 3.14; 95%CI: 1.50–6.59, p = 0.001). A ROC curve analysis showed that FLI had a significant, although poor, predictive value for assessing T2D risk (C-Statistic: 0.67; 95%CI: 0.58–0.77, p = 0.001). Higher FLI values were associated with reduced T2D-free survival (log-rank = 15.46, p < 0.001). Conclusions: FLI is significantly and independently associated with new-onset T2D risk in patients initiating statin therapy. MDPI 2023-01-30 /pmc/articles/PMC9913972/ /pubmed/36766607 http://dx.doi.org/10.3390/diagnostics13030503 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Anastasiou, Georgia
Liberopoulos, Evangelos
Petkou, Ermioni
Koutsogianni, Amalia Despoina
Adamidis, Petros Spyridwnas
Liamis, George
Ntzani, Evangelia
Barkas, Fotios
Association of Fatty Liver Index with Incident Diabetes Risk in Patients Initiating Statin–Therapy: A 6-Year Retrospective Study
title Association of Fatty Liver Index with Incident Diabetes Risk in Patients Initiating Statin–Therapy: A 6-Year Retrospective Study
title_full Association of Fatty Liver Index with Incident Diabetes Risk in Patients Initiating Statin–Therapy: A 6-Year Retrospective Study
title_fullStr Association of Fatty Liver Index with Incident Diabetes Risk in Patients Initiating Statin–Therapy: A 6-Year Retrospective Study
title_full_unstemmed Association of Fatty Liver Index with Incident Diabetes Risk in Patients Initiating Statin–Therapy: A 6-Year Retrospective Study
title_short Association of Fatty Liver Index with Incident Diabetes Risk in Patients Initiating Statin–Therapy: A 6-Year Retrospective Study
title_sort association of fatty liver index with incident diabetes risk in patients initiating statin–therapy: a 6-year retrospective study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913972/
https://www.ncbi.nlm.nih.gov/pubmed/36766607
http://dx.doi.org/10.3390/diagnostics13030503
work_keys_str_mv AT anastasiougeorgia associationoffattyliverindexwithincidentdiabetesriskinpatientsinitiatingstatintherapya6yearretrospectivestudy
AT liberopoulosevangelos associationoffattyliverindexwithincidentdiabetesriskinpatientsinitiatingstatintherapya6yearretrospectivestudy
AT petkouermioni associationoffattyliverindexwithincidentdiabetesriskinpatientsinitiatingstatintherapya6yearretrospectivestudy
AT koutsogianniamaliadespoina associationoffattyliverindexwithincidentdiabetesriskinpatientsinitiatingstatintherapya6yearretrospectivestudy
AT adamidispetrosspyridwnas associationoffattyliverindexwithincidentdiabetesriskinpatientsinitiatingstatintherapya6yearretrospectivestudy
AT liamisgeorge associationoffattyliverindexwithincidentdiabetesriskinpatientsinitiatingstatintherapya6yearretrospectivestudy
AT ntzanievangelia associationoffattyliverindexwithincidentdiabetesriskinpatientsinitiatingstatintherapya6yearretrospectivestudy
AT barkasfotios associationoffattyliverindexwithincidentdiabetesriskinpatientsinitiatingstatintherapya6yearretrospectivestudy